Klöckner Pentaplast’s Pharmaceutical & Medical Device Films Division (kp Pharma) that its Suzhou China facility is now in full operations. kp is going ahead to enhance its converting capabilities for pharmaceutical business in China by installing a state-of-the-art slitting line at its Chinese site.
The initiative in enhancing the capacity would reduce lead times and increases flexibility for all material grades to be supplied into the Chinese market through local storage and supply. The new capacity will also support the demand of Asian market
The new slitting center in China has been built conforming to the rigorous requirements of ISO 15378. The closed clean room environment of the slitting area is also in accordance with class D 100,000.
In addition, micro-biological lab (environment class C 10,000) which enables quality control covering all requirements of the CFDA regulation.
“We are seeing substantial growth in all product segments in Asia. New CFDA regulations in China are increasing the focus on the quality and performance of the packaging materials used, as well as increased demand for barrier performance to protect the sensitivity of new drugs. We are excited to make this first and significant step into China to support these trends in our market place.” said, Tracey Peacock, President, Pharmaceutical & Medical Device Films at kp.
Tracey Peacock, said, “We have been quietly adding to our capabilities in other parts of the world, and now we will accelerate the actions to address the growing Asian market place.
Asia provides exciting opportunities for kp as regulation continues to increase with many EMEA and US standards being adopted. We are excited by the opportunities in the region and this expansion, in conjunction with our local manufacturing in Thailand just the beginning of some exciting plans.”